Yposkesi, a CDMO specializing in cell and gene therapies, launched project SKY, the construction of a second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat patients living with rare and life-threatening diseases.
 
In March 2021 SK Pharmteco, a global CDMO, became a new majority equity shareholder in Yposkesi backed by an investment of approximately $71 million in the new 50,000 ft² site, making it one of the largest ATMP facilities in Europe. Project SKY will create approximately 80 new jobs by 2023.
 
With this new state-of-the-art facility, designed for European and American GMP compliance, Yposkesi will double its production surface to 100,000 ft². This new resource addresses the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.
 
Yposkesi contracted CBI, a subsidiary of Vinci Construction France, to build the facility; with Pharmaplan, an engineering service for the pharmaceutical industry, as the prime contractor.
 
The new building will house two additional production lines with several 1000L scale bioreactors. The new facility will also incorporate a centralized warehouse, capacity for media, solutions and mountings preparation as well as drug substance production suites and storage, and quality control lab resources. The plant extension is scheduled to be qualified and operational in conformance with EMA and FDA regulations in 2023.